| scholarly article | Q13442814 |
| P50 | author | Corinne Frere | Q89146447 |
| Dominique Farge | Q90288809 | ||
| Ilham Benzidia | Q91006656 | ||
| P2093 | author name string | Zora Marjanovic | |
| P2860 | cites work | Venous thromboembolic disease | Q24631121 |
| Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer | Q28186303 | ||
| Oral rivaroxaban for symptomatic venous thromboembolism | Q29620160 | ||
| Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer | Q42605270 | ||
| Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. | Q43597590 | ||
| Oral apixaban for the treatment of acute venous thromboembolism | Q43741993 | ||
| Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study | Q44086372 | ||
| Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period | Q44988252 | ||
| Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer | Q46327241 | ||
| Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis | Q46497825 | ||
| Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy? | Q46727225 | ||
| Vitamin K Antagonists after 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism | Q47173092 | ||
| Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial | Q47386644 | ||
| The effect of low molecular weight heparin on survival in patients with advanced malignancy | Q47392658 | ||
| Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria | Q47574970 | ||
| Physicians' decision about long-term thromboprophylaxis in cancer outpatients: CAT AXIS, a case vignette study on clinical practice in France. | Q47651905 | ||
| Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism | Q47682974 | ||
| Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study. | Q47829637 | ||
| A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer | Q48031013 | ||
| Effectiveness and Safety of Anticoagulants for the Treatment of Venous Thromboembolism in Patients With Cancer. | Q48111369 | ||
| Oral rivaroxaban for the treatment of symptomatic pulmonary embolism | Q49168967 | ||
| Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial | Q50137535 | ||
| Risk prediction of cancer-associated thrombosis: Appraising the first decade and developing the future. | Q50209375 | ||
| International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. | Q33404714 | ||
| Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study | Q33781172 | ||
| Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines | Q34215315 | ||
| Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism | Q34419638 | ||
| 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism | Q34436061 | ||
| Implementing thrombosis guidelines in cancer patients: a review | Q34463482 | ||
| Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report | Q34513594 | ||
| Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. | Q34546366 | ||
| Venous thromboembolism in the outpatient setting | Q34581299 | ||
| Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism | Q34655742 | ||
| Dabigatran versus warfarin in the treatment of acute venous thromboembolism | Q35016336 | ||
| Long-Term Anticoagulant Therapy of Patients with Venous Thromboembolism. What Are the Practices? | Q35664286 | ||
| Development and validation of a predictive model for chemotherapy-associated thrombosis | Q36657982 | ||
| Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology | Q36779739 | ||
| Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis | Q37404403 | ||
| New oral anticoagulants and the cancer patient. | Q37519054 | ||
| Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis | Q38248341 | ||
| Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis | Q38279947 | ||
| The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site | Q38375567 | ||
| Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. | Q38381529 | ||
| Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial | Q38405764 | ||
| Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis | Q38439334 | ||
| Predictors of recurrent venous thromboembolism and bleeding on anticoagulation. | Q38805443 | ||
| Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study | Q38829676 | ||
| Factors influencing adherence to clinical guidelines in the management of cancer-associated thrombosis. | Q38938521 | ||
| International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer | Q38979052 | ||
| Low-molecular-weight heparins for cancer-associated thrombosis: Adherence to clinical practice guidelines and patient perception in TROPIQUE, a 409-patient prospective observational study. | Q39171173 | ||
| Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European society of cardiology working groups of aorta and peripheral circulation and pulmonary circulation and right ventricular function. | Q39229601 | ||
| Effect of syringe size on bruising following subcutaneous heparin injection | Q39430237 | ||
| Validation of the clinical prediction rule for recurrent venous thromboembolism in cancer patients: the Ottawa score | Q39446006 | ||
| Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. | Q39540721 | ||
| Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study | Q39949914 | ||
| Cohort Study on the Management of Cancer-Associated Venous Thromboembolism Aimed at the Safety of Stopping Anticoagulant Therapy in Patients Cured of Cancer | Q40031451 | ||
| Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study | Q41133589 | ||
| Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. | Q41552439 | ||
| A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study. | Q50619669 | ||
| Low discriminating power of the modified Ottawa VTE risk score in a cohort of patients with cancer from the RIETE registry. | Q50639054 | ||
| Prediction of venous thromboembolism in cancer patients. | Q51662626 | ||
| Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. | Q52339910 | ||
| Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. | Q53083500 | ||
| Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. | Q53273545 | ||
| Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. | Q53337476 | ||
| Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. | Q53589375 | ||
| Quality of life in cancer patients undergoing anticoagulant treatment with LMWH for venous thromboembolism: the QUAVITEC study on behalf of the Groupe Francophone Thrombose et Cancer (GFTC). | Q55252651 | ||
| The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation | Q56968736 | ||
| Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences | Q57163141 | ||
| Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry | Q57215887 | ||
| Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer | Q57689134 | ||
| A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score | Q57758028 | ||
| Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D) | Q61860158 | ||
| Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer | Q82597285 | ||
| Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism | Q84330472 | ||
| Clinical Course of Venous Thromboembolism in Patients with Pancreatic Cancer: Insights from the RIETE Registry | Q88429406 | ||
| Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study | Q88494004 | ||
| A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts | Q89051081 | ||
| Apixaban to Prevent Venous Thromboembolism in Patients with Cancer | Q90240985 | ||
| Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH | Q90357781 | ||
| Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis | Q90480224 | ||
| Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study | Q90637386 | ||
| Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study | Q90920183 | ||
| Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug-drug interactions | Q93191277 | ||
| The risk of recurrent VTE and major bleeding in a commercially-insured population of cancer patients treated with anticoagulation | Q93357580 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | low molecular weight heparin | Q2750727 |
| venous thromboembolism | Q9397786 | ||
| thrombosis | Q261327 | ||
| P304 | page(s) | 71 | |
| P577 | publication date | 2019-01-10 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges | |
| P478 | volume | 11 |
| Q64085268 | Comparison of Treatment Result Between Anticoagulation Alone and Catheter-Directed Thrombolysis Plus Anticoagulation in Acute Lower Extremity Deep Vein Thrombosis |
| Q92991920 | Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019? |
| Q92662638 | Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools |
| Q92200830 | Retrospective evaluation of the efficacy and safety of rivaroxaban in patients with cancer-associated venous thromboembolism: A single-center study |
| Q64244258 | The History of Armand Trousseau and Cancer-Associated Thrombosis |
| Q93061001 | Women, thrombosis, and cancer |
| Q92237284 | [Perioperative Venous Thromboembolism (VTE) Prophylaxis in Thoracic Cancer Patients: Chinese Experts Consensus - Interpretation of Application Prospect of Direct Oral Anticoagulant] |
Search more.